phrykt

Unicycive Therapeutics, Inc. (UNCY): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of UNCY were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Unicycive Therapeutics

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns UNCY

80 funds and institutions reported UNCY shares worth $61.6M at the end of Q2 2026, about 52% of the company. The largest holder is Nantahala Capital Management, LLC with 11.1%.

Funds and institutions (13F) 52%Everyone else 48%

10 largest owners, by share of the company

Nantahala Capital Management, LLC11.1%
BlackRock, Inc.5.6%
Vanguard Capital Management LLC4.2%
Octagon Capital Advisors LP4.0%
Geode Capital Management, LLC2.2%
Vivo Capital, LLC2.2%
Marshall Wace, LLP2.2%
Logos Global Management LP1.9%
State Street Corp1.8%
Diametric Capital, LP1.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Nantahala Capital Management, LLC2.80M11.11%$13.1M+198%
BlackRock, Inc.1.41M5.60%$6.6M+3837%
Vanguard Capital Management LLC1.07M4.25%$5M+32%
Octagon Capital Advisors LP1.00M3.96%$4.7MNo change
Geode Capital Management, LLC564,0192.23%$2.6M+177%
Vivo Capital, LLC550,0002.18%$2.6M-69%
Marshall Wace, LLP547,8622.17%$2.6M+254%
Logos Global Management LP473,5631.88%$2.2MNo change
State Street Corp450,1621.78%$2.1M+463%
Diametric Capital, LP374,1321.48%$1.8M+366%
J. Goldman & Co LP327,3451.30%$1.5MNew
Diadema Partners LP303,6761.20%$1.4M+186%
Millennium Management LLC271,4561.08%$1.3M-81%
Dauntless Investment Group, LLC214,0000.85%$1M+45%
Citigroup Inc182,6540.72%$857K+18265300%
Northern Trust Corp181,9300.72%$853K+406%
Vanguard Portfolio Management LLC169,1960.67%$794KNew
Susquehanna International Group, LLP160,0390.63%$751K-20%
Jump Financial, LLC153,0000.61%$718KNew
Vanguard Fiduciary Trust Co148,9650.59%$699K+47%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No UNCY insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

UNCY short interest

High short interest. 17.3% of UNCY shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 137%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.82M UNCY shares were sold short, 17.3% of the shares outstanding, down 1.2% from the report before. At the average daily volume of 1.15M shares, buying them all back would take about 4.2 trading days (days to cover).

Shares short, % of all shares

17.3%May 15Oct 3021.3%

Days to cover

4.2May 15Oct 306.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.82M17.30%-1%1.15M4.2
Oct 15, 20264.88M17.51%+1%1.01M4.8
Sep 30, 20264.85M17.43%+15%846,0335.7
Sep 15, 20264.20M15.09%+7%905,1974.6
Aug 31, 20263.91M14.04%-6%668,8145.8
Aug 14, 20264.15M14.91%-4%761,1195.5
Jul 31, 20264.33M17.16%-12%852,3365.1
Jul 15, 20264.94M19.57%+6%1.94M2.5
Jun 30, 20264.67M18.51%+44%3.90M1.2
Jun 15, 20263.24M12.82%+14%884,5043.7
May 29, 20262.84M11.24%+40%752,2153.8
May 15, 20262.03M8.04%-6%631,0863.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Unicycive Therapeutics company events

Unicycive Therapeutics filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Sep 29, 2026.

  1. Sep 29, 2026LeadershipUnicycive Therapeutics, Inc. appointed Meredith S. Manning as an independent director on the Company’s board of directors, effective October 1, 2026. Filing
  2. Sep 28, 2026AnnouncementA securities class action lawsuit was filed in United States District Court for the Northern District of California against Unicycive Therapeutics, Inc. and certain of its officers. Filing
  3. Aug 12, 2026ResultsReleased financial results. Filing
  4. Jul 2, 2026AnnouncementThe Company had an ending cash balance of approximately $61.4 million as of June 30, 2026. Filing
  5. Jun 22, 2026VoteReported shareholder vote results. Filing
  6. Jun 5, 2026AgreementAs previously reported, Unicycive Therapeutics, Inc. entered into a Sales Agreement, dated November 13, 2024, with Guggenheim Securities, LLC, as sales agent as amended by Amendment No. 1 to Sales Agreement dated November 14, 2025, between the Company and the Agent (as amended, the “Sales… Filing
  7. May 12, 2026ResultsReleased financial results. Filing
  8. Apr 6, 2026LeadershipGaurav Aggarwal, a director of Unicycive Therapeutics, Inc., resigned from the Board of Directors of the Company. Filing
  9. Mar 30, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Unicycive Therapeutics financials

Famous investors that hold UNCY

2 of the 50 well-known investors we track reported holding UNCY in their latest 13F filing. The largest position is Israel Englander's, worth $2.3M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026497,446$2.3M0.0%+83%
Ken Griffin · Citadel AdvisorsQ3 2026105,262$494K0.0%+72%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named UNCY in the last 120 days.

FiledHolderFormStake
Nov 16, 2026RA Capital Management, L.P.13G/A9.9%
Nov 16, 2026Vivo Opportunity Fund Holdings, L.P.13G/A10.0%
Nov 16, 2026RA Capital Management, L.P.13G/A9.9%
Nov 16, 2026Vivo Opportunity Fund Holdings, L.P.13G/A10.0%

Questions about Unicycive Therapeutics, Inc. (UNCY) stock

Who owns the most UNCY stock?

The largest reported owner of Unicycive Therapeutics, Inc. (UNCY) is Nantahala Capital Management, LLC, with 11.1% of the company. In total, 80 funds and institutions reported holding UNCY at the end of Q2 2026, together about 52% of the shares. See the largest owners.

Are UNCY insiders buying or selling?

No UNCY insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in UNCY?

As of Oct 30, 2026, 4.82M UNCY shares were sold short, 17.3% of the shares outstanding, down 1.2% from the report before. At the average daily volume of 1.15M shares, buying them all back would take about 4.2 trading days (days to cover). See the history.

Which famous investors hold UNCY?

2 of the 50 well-known investors we track reported UNCY in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $2.3M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.